Revolution Medicines gets approval for daraxonrasib in metastatic pancreatic cancer
Regulators approved daraxonrasib for patients with metastatic pancreatic adenocarcinoma. Revolution Medicines is described as having received the landmark approval of its pancreatic cancer pill late last month.
Revolution Medicines barely had time to celebrate the approval of its pancreatic cancer pill before Wall Street wanted to know what comes next. Late last month, regulators approved daraxonrasib for patients with metastatic pancreatic adenocarcinoma. Marketed under the brand name, the drug is now approved for that use.